Mineralys Therapeutics Stock (NASDAQ:MLYS)
Previous Close
$13.35
52W Range
$8.24 - $18.38
50D Avg
$12.47
200D Avg
$12.31
Market Cap
$858.96M
Avg Vol (3M)
$1.11M
Beta
-0.39
Div Yield
-
MLYS Company Profile
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.